Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
- PMID: 16173015
- DOI: 10.1002/jmv.20462
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
Abstract
Both highly potent antiretroviral drug rescue multi therapy and treatment interruption (TI) have been suggested to be effective in HIV-1 infected-patients with multiple treatment failure. GigHAART-ANRS 097 was the only randomized trial during which an 8-week TI was beneficial in heavily pre-treated patients with multi-drug resistant virus on resuming a multiple-drug salvage regimen. The aim of this study was to analyze virological and pharmacological factors associated with a virological response. Clonal resistance analysis showed that although the viral population was highly mutated and nearly monoclonal at baseline, the 8-week interruption therapy allowed the re-emergence of more susceptible quasispecies to the subsequent salvage therapy, which were not detected by classical genotypic resistance testing. The fact that not every viral clone harbored all resistance viral mutations could explain a part of the virological response to a six to eight drug regimen for patients enrolled in the TI group. This phenomenon was associated with a transient virological response after the use of a GigHAART therapy, but was followed by the re-emergence of baseline resistance pattern and acquisition of additional mutations in patients failing this strategy. A combined factor of protease inhibitor (PI) concentration and genotypic score, expressed as a genotypic inhibitory quotient (GIQ), was used to assess the importance of genotypic resistance and plasma drug levels in the rate of response to multiple PI combination. The GIQ of each PI used in the regimen was not associated with virological success. However, the sum of PI GIQs was predictive of a virological response. These results suggest that pharmacological enhancement might overcome viral resistance and that there is some benefit in adding the activity of several boosted-PIs to improve the response to a salvage regimen.
(c) 2005 Wiley-Liss, inc.
Similar articles
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.J Med Virol. 2006 Dec;78(12):1537-41. doi: 10.1002/jmv.20736. J Med Virol. 2006. PMID: 17063520
-
Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.J Med Virol. 2002 Nov;68(3):305-10. doi: 10.1002/jmv.10204. J Med Virol. 2002. PMID: 12226815
-
Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.Antivir Ther. 2003 Oct;8(5):443-54. Antivir Ther. 2003. PMID: 14640392 Clinical Trial.
-
The clinical significance of viral fitness.J HIV Ther. 2005 Mar;10(1):6-10. J HIV Ther. 2005. PMID: 15951728 Review.
Cited by
-
Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.J Proteome Res. 2013 May 3;12(5):2282-94. doi: 10.1021/pr400185w. Epub 2013 Apr 17. J Proteome Res. 2013. PMID: 23544708 Free PMC article.
-
Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.Antimicrob Agents Chemother. 2009 Oct;53(10):4153-8. doi: 10.1128/AAC.00041-09. Epub 2009 Jul 13. Antimicrob Agents Chemother. 2009. PMID: 19596874 Free PMC article.
-
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.Blood. 2006 Oct 15;108(8):2827-35. doi: 10.1182/blood-2006-03-012534. Epub 2006 Jun 29. Blood. 2006. PMID: 16809617 Free PMC article.
-
Direct injection HILIC-MS/MS analysis of darunavir in rat plasma applying supported liquid extraction.J Pharm Anal. 2015 Feb;5(1):43-50. doi: 10.1016/j.jpha.2014.05.001. Epub 2014 May 20. J Pharm Anal. 2015. PMID: 29403914 Free PMC article.
-
HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.J Med Virol. 2010 Feb;82(2):187-96. doi: 10.1002/jmv.21677. J Med Virol. 2010. PMID: 20029816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous